2.36
+0.04(+1.72%)
Currency In USD
| Previous Close | 2.32 |
| Open | 2.33 |
| Day High | 2.53 |
| Day Low | 2.32 |
| 52-Week High | 4.3 |
| 52-Week Low | 1.57 |
| Volume | 76,177 |
| Average Volume | 112,525 |
| Market Cap | 34.81M |
| PE | 0.72 |
| EPS | 3.29 |
| Moving Average 50 Days | 2.86 |
| Moving Average 200 Days | 2.37 |
| Change | 0.04 |
If you invested $1000 in VYNE Therapeutics Inc. (VYNE) since IPO date, it would be worth $1.14 as of February 05, 2025 at a share price of $2.36. Whereas If you bought $1000 worth of VYNE Therapeutics Inc. (VYNE) shares 5 years ago, it would be worth $6.5 as of February 05, 2025 at a share price of $2.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
GlobeNewswire Inc.
Jan 06, 2025 12:30 PM GMT
Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial expected in mid-2025“Repibresib” approved as the non-proprietary name for VYN201 by USAN BRIDGEWATER, N.J., J
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
GlobeNewswire Inc.
Dec 23, 2024 12:30 PM GMT
Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable safety and tolerability profile with no drug-relate
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
Nov 07, 2024 1:00 PM GMT
VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD data expected in Q4 2024 BRID